Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
ORVMF$1.19-0.05(-4.03%)ORVANA REPORTS H2 FY2026 EXPLORATION RESULTS AT OROVALLE, SPAIN Orvana Minerals Corp. (TSX: ORV) (OTCQX: ORVMF) ("Orvana" or the "Company") is pleased to report exploration results from its El Valle and Carlés...[7:30:00 PM ET]FHB$25.63+0.22(+0.87%)First Hawaiian, Inc. and TriCo Bancshares Announce Shareholder Approvals of Acquisition[7:00:00 PM ET]BMO$175.88+2.05(+1.18%)Stonepeak Completes Acquisition of BMO's Transportation and Vendor Finance Businesses and Launches Longview Capital Solutions[6:39:00 PM ET]TCBS$17.28+0.18(+1.05%)TEXAS COMMUNITY BANCSHARES, INC. AND THE BANC OF SAN JACINTO COUNTY BANCSHARES, INC., THE PARENT OF THE BANK OF SAN JACINTO COUNTY, COLDSPRING, TEXAS, ANNOUNCE MERGER AGREEMENT Texas Community Bancshares, Inc. (NASDAQ: TCBS) (the "Company") and The Banc of San Jacinto County Bancshares, Inc. ("SJCB") jointly announced today...[6:39:00 PM ET]BDIMF$14.03+0.28(+2.03%)Black Diamond Reports Strong Third Quarter Results with Record Consolidated Revenue and Increases Dividend by 22%[6:32:38 PM ET]WPRT$2.220.00(0.00%)Aetherion to Issue Q3 2026 Financial Results on November 12, 2026[6:30:00 PM ET]LSF$2.67-0.02(-0.74%)Laird Superfood to Report Third Quarter 2026 Financial Results on November 12, 2026[6:30:00 PM ET]BMO$175.88+2.05(+1.18%)BMO Closes Sale of Transportation and Vendor Finance Businesses BMO Financial Group (TSX: BMO) (NYSE: BMO) today announced it has closed the previously announced sale of its Transportation Finance and Vendor...[6:30:00 PM ET]LEGH$28.93+0.53(+1.87%)Legacy Housing Corporation Announces Timing of Third Quarter 2026 Earnings Release and Conference Call[6:18:08 PM ET]BFST$32.27+0.63(+1.99%)Business First Bancshares, Inc. Announces Stock Repurchase Program[6:15:00 PM ET]

BBIO · NASDAQ

BridgeBio Pharma, Inc.

$70.69 -0.13 (-0.18%)

Company overview

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs with product candidates ranging from early discovery to late-stage development. Its products include AG10 and BBP-265, a small molecule stabilizer of transthyretin (TTR) in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy (ATTR-CM); BBP-831, a small molecule selective FGFR1-3 inhibitor in Phase 2 clinical trial for achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate in Phase 2 clinical trial for congenital adrenal hyperplasia (CAH) driven by 21-hydroxylase deficiency (21OHD).

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$13.8B
Employees
725
Headquarters
Palo Alto, CA
Website
bridgebio.com
CEO
Neil Kumar
Listed
June 27, 2019
P/E
-18.85
Dividend yield
0.00%

Company financials

Revenue
$580M
Gross profit
$544M
Operating income
-$571M
EBITDA
-$601M
Net income
-$726M
EPS
-$3.75
Total assets
$1.4B
Total debt
$3.4B
Gross margin
93.78%
Net margin
-125.17%
Earnings yield
-5.30%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

No geographic segmentation.

Showing FY 2025

Price chart

61.2669.6177.9686.3094.65
BBIO 1D NASDAQ O69.10H71.18L68.65C70.82+1.45 (+2.09%)Vol3.11M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
BBIOBridgeBio Pharma, Inc. Stock news BridgeBio Pharma (BBIO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates Zacks Investment Research
BBIOBridgeBio Pharma, Inc. Stock news BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue Estimates Zacks Investment Research
BBIOBridgeBio Pharma, Inc. Stock news BridgeBio Pharma Q3 2026 Earnings Call Transcript Benzinga
BBIOBridgeBio Pharma, Inc. Press release BridgeBio Reports Third Quarter 2026 Financial Results and Corporate Updates GlobeNewswire
BBIOBridgeBio Pharma, Inc. Press release BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET GlobeNewswire
BBIOBridgeBio Pharma, Inc. Press release BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
BBIOBridgeBio Pharma, Inc. Stock news BridgeBio: Maintaining 'Strong Buy' Additional Encaleret Data ADH1 And Three Expected FDA Reviews Seeking Alpha
BBIOBridgeBio Pharma, Inc. Press release Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records GlobeNewswire
BBIOBridgeBio Pharma, Inc. Press release Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1 GlobeNewswire
BBIOBridgeBio Pharma, Inc. Press release BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026 GlobeNewsWire
BBIOBridgeBio Pharma, Inc. Press release BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting GlobeNewsWire
BBIOBridgeBio Pharma, Inc. Press release BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia GlobeNewsWire
BBIOBridgeBio Pharma, Inc. Press release BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day GlobeNewsWire
BBIOBridgeBio Pharma, Inc. Press release BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels GlobeNewsWire
BBIOBridgeBio Pharma, Inc. Stock news BridgeBio Pharma Eyes Four Global Launches by 2027 as Attruby Nears Blockbuster Status MarketBeat
BBIOBridgeBio Pharma, Inc. Stock news BridgeBio Pharma Eyes Four Global Launches by 2027 as Attruby Nears Blockbuster Status Defense World
BBIOBridgeBio Pharma, Inc. Stock news BridgeBio Pharma, Inc. (BBIO) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript Seeking Alpha
BBIOBridgeBio Pharma, Inc. Press release Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening GlobeNewsWire
BBIOBridgeBio Pharma, Inc. Press release BridgeBio Pharma Reports Inducement Grants under Nasdaq GlobeNewswire
BBIOBridgeBio Pharma, Inc. Stock news BridgeBio Pharma, Inc. (BBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Seeking Alpha
See more
FAQ

Questions about BridgeBio Pharma, Inc.

What does BridgeBio Pharma, Inc. do?
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs with product candidates ranging from early discovery to late-stage development. Its products include AG10 and BBP-265, a small molecule stabilizer of transthyretin (TTR) in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy (ATTR-CM); BBP-831, a small molecule selective FGFR1-3 inhibitor in Phase 2 clinical trial for achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate in Phase 2 clinical trial for congenital adrenal hyperplasia (CAH) driven by 21-hydroxylase deficiency (21OHD).
What is BBIO's market cap?
BridgeBio Pharma, Inc. (BBIO) is a listed stock with a live quote. The latest market cap on this page is $13.8B.
Where is BridgeBio Pharma, Inc. headquartered?
BridgeBio Pharma, Inc. is headquartered in Palo Alto, CA.
How do I get BBIO news from the API?
Call GET /v1/news?tickers=BBIO. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does BBIO news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for BBIO, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the BBIO price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs